Breast Cancer First-line Treatment with CDK4/6 Inhibitor
We are pleased to present an insightful case study on managing the adverse effects associated with breast cancer treatment. This case study is presented by our esteemed Key Opinion Leader (KOL), Dr. Wendy Chan, a renowned expert in oncology and patient care. Dr. Chan will delve into the details of a patient's journey, focusing on practical strategies to manage treatment-related side effects while maintaining the patient's quality of life.
Promote Risk-Adapted Treatment Strategies for Early Breast Cancer
Dr. Dhanusha Sabanathan discussed the importance of risk-adapted treatment strategies for early breast cancer.
HR+ and HER2- Metastatic Breast Cancer
Professor Hilary Martin discusses HR+ and HER2- metastatic breast cancer
Early stage high risk ER+/HER2- Breast Cancer
Dr. Nick Zdenkowski discusses a case of early-stage, high-risk breast cancer, detailing the patient's diagnosis, treatment plan, and outcomes.
Dr. Sabanathan Case Study
Dr. Dhanusha Sabanathan, a medical oncologist from Sydney, presents cases of metastatic breast cancer, highlighting the effectiveness of the latest medications in treating metaplastic triple-negative breast cancer with minimal side effects.